5/4/2023

speaker
Nick Moscato
Chief Strategy Officer

Greetings and welcome to the Ametis' fourth quarter 2022 earnings conference call. At this time, all participants are on a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Mr. Nick Moscato, Chief Strategy Officer. Thank you. Please go ahead.

speaker
Emeticis IR Representative
Investor Relations

Thank you, Operator, and welcome to the Emeticis Investor Conference call to discuss the results of the fourth quarter and year-ended December 31, 2022. A copy of our press release, supplemental slides, and related Form 8K filing with the SEC are available on the Investor Relations page of our website. Speaking on today's call from Emeticis will be Paul Cucero, Chairman and CEO, and Scott Ginn, CFO and Acting COO. Before we get started with our call, I would like to remind everyone that statements made on this conference call today may constitute forward-looking statements and are protected under the safe harbor of the Private Security Litigation Reform Act. These forward-looking statements are based on information available to Emeticis today. The company assumes no obligation to update information provided on this call to reflect subsequent events other than is required under applicable security laws. These forward-looking statements may involve a number of risks and uncertainties which may cause the company's results or actual outcomes to differ materially from such statements. These risks and uncertainties include factors detailed in our SEC filings, including our Forms 10-K, 10-Q, and 8-K. In addition, as required by SEC Regulation G, a reconciliation of any non-GAAP measure mentioned during our call today to the most comparable GAAP measure will also be available in our Forms 10-K, 10-Q, and 8-K. Thank you, and I'll turn the call over to Amedisys Chairman and CEO, Paul Kucereau.

speaker
Paul Cucero
Chairman & CEO

Thanks, Nick. Hello, everyone, and welcome to the Amedisys fourth quarter and year-end 2022 earnings call. It's a privilege to be back and talking to you all again. In the few short months I've been back as CEO, I've had the distinct pleasure of spending time in the field with our clinicians, who provide the highest quality care to their patients wherever they call home. What you do on a daily basis is truly inspiring and reaffirms to me more than ever that the future of a medicis is extraordinary and unique. Despite a choppy 2022, our 20,000 plus associates have successfully steered us to deliver results that we can really be proud of. As I've returned as CEO, The two questions I get are, one, what's changed, and two, what are you going to focus on? Our world has definitely changed. There's no question about it. As the philosopher Heraclitus said, you can never step into the same river twice, and that's certainly the case in our industry. Our world is rapidly evolving, but mercifully, the trends are moving towards emeticists and our industries, not away from us. There's a new paradigm driven by consumerism, demographics, advances in care delivery, and cost of driving care into the home. Various elements of our world are evolving at different speeds. Regulators, some of our Medicare Advantage partners are moving more slowly than we would like. Others are seeing where this is going and are actively innovating with us to meet us where the world is evolving towards. Change creates opportunity. Accelerated change creates dynamic opportunity. We're in a time of rapid change. Hence, my excitement and enthusiasm for how we have positioned ourselves and the opportunities that will come. So what's different? First, there is a significant clinical labor shortage, especially in nursing. COVID did a number on field-based clinicians. Demand is outstripping supply more dramatically than ever. This is likely to continue. The winners in our world will be those companies that have the capacity to fulfill the demand. Second, our mix of payers is changing. Medicare Advantage is growing faster than fee-for-service. Some of our Medicare Advantage partners are enlightened and are working with us to secure the labor capacity they will need. Others are trying to play the old game of low per visit rates and expecting in an inflationary environment to keep their rates artificially low. The industry just can't do it. Neither can we. When scarcity increases, demand goes up, and we are now in a new world where we must pick which visits we take or won't take. We're working through this now, giving all our partners an opportunity to understand what's going on in this emerging environment. Helping drive this change is consolidation in our industry, scarcity of supply, and increasingly long lengths of stays in hospitals, which are driving an already stretched business into further losses. Many of our payer partners are talking about increased post-acute spend, much due to lack of availability in at-home care. We are the most efficient alternative of all the post-acute options and will increase our share of post-acute spend as we move up the acuity spectrum. Home health and emeticists in particular are the most cost-efficient alternative of the post-acute options. And we will increase our share of post-acute spend as we move our way up the acuity spectrum. So increasingly, payers will be coming to Home Health, and we believe disproportionately to Amedisys, as we are arguably the only company taking true post-acute risks. So changing times, exciting times. Now, how are we going to go out and get what's ours? The answer is four strategic initiatives which we think will best drive our caregiving and business results. They are One, people. As I said, luckily the world has changed. It's all about recruiting, developing, and retaining our clinicians, which drives our ability to grow and continue to provide the best in class clinical quality Amedisys has become known for. We're rapidly emerging into a capacity constrained industry. Those that have the workers will win. We're the best, but that isn't good enough in this environment. We're going to be better. will continue to be the best place where clinicians want to come and deliver the highest quality care in the home. We're seeing strong results early on, especially in recruiting, as we double down on our focus here, as January was our highest single month of starts in a medicine's history. Two, growth. As capacity becomes a foundational issue, we will have to choose our partners carefully. This is a new world for us and we will not be commoditized. We will drive predictable results and outpace the industry's growth in both home health and hospice while managing our precious clinical capacity to make sure that we can take all the patients that are coming to us. As Medicare Advantage continues to outpace fee-for-service growth, we need to align with partners who can pay us enough to deliver the quality care that's needed for their members. Next, Clinical optimization and automation. We must remove as much of the administrative burden from our care center staff and allow them to build a focused care center culture where clinicians want to be so that they can provide the highest quality care to our patients. These are self-initiated efficiency moves. It's totally in our hands to drive this initiation successfully, which we will do. And last, Contessa. Our high acuity segment truly differentiates us from our competition while opening up wholly new markets and growth opportunities in places few, if any, others can go. It is up to us to go show you all what this highly innovative asset can be by continuing to grow it and making it profitable. High acuity risk-based care in the home is the future. We see the tremendous demand. Our partners are asking for more, and we're committed to giving them more. It's a good situation when demand for your product is so strong. These are the big four. That's what we'll measure ourselves on. We'll report out to you on these measures and their impacts as we progress through the year. Now, let's dive a little deeper into each and what you should expect in 2023. Growth and people are joined at the hip. As I mentioned, demand for our services is at an all-time high, while access to clinicians to fulfill this increase in demand has been challenged. In order to service the increased number of referrals, we must have the clinical capacity to do so. As we continue to dig into our employees' data, we have found that 66% of clinical turnover happens in year one, a dynamic we are aggressively changing. As mentioned, our enhanced talent acquisition team has done a great job bringing more qualified clinicians on board, but we must keep them once they are here. In fact, from August 2022 through January 2023, we had 26% more nursing starts than January through July of 22, and January of 2023 was our best month ever for overall offers. So what else are we doing about staffing? We are going further and creating an unrivaled people experience here at Amedisys by simplifying our administrative processes, enabling our caregivers with tools to make their jobs easier, improving our leadership development for our 550 dues, streamlining our onboarding processes, investing in our employees, and rolling out an enhanced benefit package specifically focused on aligning with what is important to our clinicians. The combination of these activities will truly enable Amedisys to hold its position as the healthcare employer of choice. It will decrease our turnover, increase our clinical capacity, and in turn, continue to supercharge our growth. We've done it before, we'll do it again, and we will update you on how we're doing. Growth has been and always will be a key initiative for Amedisys. Although the way in which we think about growth has been challenging as our markets look different today than they have in the past, the demand for our services and home health is at an all-time high as patients and payers continue to recognize and demand that more and more care can be delivered in the home. That is where patients want to be and the costs are less than any other site of care while we deliver outcomes that are equal and in many times better than institutional care. Hospice is the same, high demand to die with dignity at home. We know that the industry over the medium term should be growing at a mid single digit pace. What has been different for us has been where the growth is coming from. Historically, fee for service has been our main driver of revenue growth. However, as Medicare Advantage penetration continues to significantly outpace fee for service growth, we must think differently. about how and where we grow. Amedisys has been at the forefront of working with Medicare Advantage plans for the past number of years. We have executed innovative case rate contract with our partners at CVS and Aetna and figured out ways to work strategically with our convener partners and at the same time have taken market share and fee for service. We have developed great relationships with some plans who recognize how our quality and scale differentiates us from our peers. That said, not all plans are created equal, and for those plans that continue to view us simply as a cheap per-visit provider and won't recognize that labor inflation is real and try to simply cram lower rates and lower utilization on us, we will no longer be working with them. We just can't afford to. We have a finite amount of clinical capacity, and we must be paid in a manner that allows us to provide quality of care with the excellent outcomes a medicine is known for. If plans do not want to partner with us on reasonable terms, we will have to cancel contracts and defer our capacity to our strategic partners who value our results. In order to allow our clinicians to focus on what matters most, patient care, our care center leadership focusing on building culture that recruits and retains the best people, we will continue with the clinical optimization activities we rolled out in the second half of 2022. We want to remove as much of the administrative burden as is possible in our care centers. This will not only drive improved and focused culture, but it will allow us to scale our infrastructure in a more cost-effective manner while building in yet another layer of efficiency and accuracy across our processes. To date, we have centralized our volunteer and bereavement services across our hospice locations, our intake functions across home health, and we have a number of other pilots set to roll out in 2023. As Scott will discuss, the impact of these initiatives will drive nearly $20 million in cost savings in 2023, and we should see another step up in savings as we enter 2024. Finally, Contessa, our innovative high acuity care acquisition that closed in August of 2021 has not been immune to the impacts of hospital performance and the labor environment that has had its effect on healthcare services. Though we recognize we are behind our original plan, we are growing nicely and planfully. We have tremendous conviction for what Contessa does, where it will take us, and the growth potential for its lines of business. In fact, in Q4, total admissions from hospital and SNF at home were 482 representing a 69% growth rate year over year. For full year 2022, we treated 607 patients in our hospital and SNF programs representing 100 plus percent growth year over year. Contessa is focused on mining and growing our core partnerships while executing two to three new partnerships a year. The patients we admitted to these high acuity models continue to generate positive clinical and financial outcomes. Our patient satisfaction remains in excess of 85%, and these programs continue to deliver on quality by driving down repeat hospitalizations when compared to traditional care pathways. Our ability to reduce patients' total cost of care through high touch clinical management continues to track with our expectations for MLR performance. We are also excited with the recent regulatory development in this space. As part of the omnibus spending bill that became law on December 29th, 2022, CMS extended the acute hospital care at home initiative until December 31st, 2024. While Contessa's work began much before the public health emergency, the CMS initiative began during the pandemic as a way to address the safe expansion of hospital capacity. With this recognition and extended acceptance of hospital at home programs by CMS, our view is that we are likely to see acceleration of the proliferation of high acuity in home programs in years to come. Lastly and most importantly, I've been out visiting our JV partners, and the biggest issue they have with us is they want more, faster. A good situation to be in when your customer's main issue is they can't get enough of what you have. We are focused on scaling our operations up. The potential of each of our partners is enormous. As Scott will lay out in our 2023 guidance, revenue at Contessa will be nearly $50 million driven by increased volume from our current JV partners, new volume from JVs we have recently signed but not implemented, and maybe most excitingly, our new risk partnership with Blue Cross Blue Shield of Tennessee to provide palliative care services at home. This new innovative partnership really showcases the power of a combined emeticist and Contessa clinical asset, and we are thankful for our partners at Blue Cross Blue Shield of Tennessee and their desire to disrupt how health care is provided to their high-acuity Medicare Advantage members. In our palliative care at-home model, Blue Cross Blue Shield of Tennessee's members can receive palliative care in person or via telehealth from a Medicis' clinicians including doctors, nurse practitioners, and nurses at no additional cost. We started with a Middle Tennessee rollout in January and have plans to expand to the entire state as we prove out performance in the model. I'm incredibly excited by this opportunity and you all should be expecting more innovative partnerships like this to come in the future. Much like our core lines of business, our pipeline of future growth opportunities remains strong and exciting. We continue to make significant progress in our pursuit of direct relationships with health systems, looking for the leading comprehensive care at home partner, as well as health plans interested in innovative value-based arrangements for in-home services, including palliative care. In other news, we announced yesterday that we will be divesting the operational portion of our personal care line of business to HouseWorks, a Massachusetts-based operator of personal care assets, and in turn adding HouseWorks to our personal care network. We continue to believe in the need for and the importance of personal care services as a key piece of whole person care. And as such, we are committed to continuing to push to grow the utilization of our personal care network. As we continue to work on contract innovation with managed care, having access to personal care services across our nationwide footprint will be a key value driver. Our commitment is to contract and build networks with personal care at this point, not to own it. With that, I'll turn it over to Scott, who will take us through our Q4 performance and a more detailed review. of our operational and financial performance for the quarter and our projections for 2023. Scott?

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-